Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Other lung indications program 1
- Development stage
- Preclinical
- Lead developer
- ReCode Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
Other lung indications program 1 is a discovery-stage therapeutic research program developed by ReCode Therapeutics. The program utilizes the company's proprietary Selective Organ Retargeting (SORT) lipid nanoparticle (LNP) delivery platform to target undisclosed pulmonary diseases. This technology is designed to enable organ-specific and cell-specific delivery of therapeutic payloads, such as mRNA or gene correction tools, directly to the lungs via inhalation. By bypassing the limitations of traditional LNP delivery, which often accumulates in the liver, the SORT LNP platform allows for the treatment of a broader range of respiratory conditions beyond the company's lead programs in cystic fibrosis and primary ciliary dyskinesia.
- Other names
- Other lung indications programReCode Therapeutics-Undisclosed-Multiple-Inhaled (respiratory) (inferred)-Other lung indications
Beyond the preview
Go deeper on Other lung indications program 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Other lung indications program 1.